GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation.
Aromatase inhibitors can be utilized to minimize oestrogen exposure in breast cancer patients undergoing gonadotrophin stimulation. This retrospective-prospective study determined whether using a gonadotrophin-releasing hormone agonist (GnRHa) trigger instead of human chorionic gonadotrophin (HCG) would reduce oestrogen exposure and improve cycle outcomes in aromatase inhibitor cycles. Seventy-four breast cancer patients who desired fertility preservation, with normal ovarian reserve and < 45 years of age received letrozole 5mg/day plus recombinant FSH 150-300 IU/day for ovarian stimulation. Subjects either received HCG 5000-10,000 IU (n=47) or leuprolide acetate 1mg (GnRHa, n=27) as trigger. Oestradiol measurements were repeated 4 days after the trigger and subjects were evaluated for ovarian hyperstimulation syndrome (OHSS). In the GnRHa group, oestradiol concentrations dropped significantly after the trigger than the HCG group (P=0.013) and there was a lower incidence of OHSS. GnRHa trigger resulted in a higher number and percentage of mature oocytes and a higher number of cryopreserved embryos or oocytes compared with HCG. GnRHa trigger improves outcomes by increasing the yield of mature oocytes and embryos in aromatase inhibitor cycles and also decreases the post-trigger oestradiol exposure as well as OHSS risks in women with breast cancer.
Oktay
Kutluk
K
Department of Obstetrics and Gynecology, Division of Reproductive Medicine and Institute for Fertility Preservation, New York Medical College/Westchester Medical Center, Valhalla, NY 10595, USA. koktay@fertilitypreservation.org
Türkçüoğlu
Ilgın
I
Rodriguez-Wallberg
Kenny A
KA
D000328:Adult; D047072:Aromatase Inhibitors / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000503:physiopathology*; D005260:Female; D005298:Fertility; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology*
D047072:Aromatase Inhibitors; D009570:Nitriles; D011994:Recombinant Proteins; D014230:Triazoles; D007987:Gonadotropin-Releasing Hormone; D000077289:Letrozole; D005640:Follicle Stimulating Hormone
J Natl Cancer Inst. 2008 Nov 19;100(22):1643-8
19001605
Fertil Steril. 2004 Jan;81(1):1-5
14711532
Fertil Steril. 2000 May;73(5):883-96
10785212
Fertil Steril. 2003 Nov;80(5):1309-14
14607613
Fertil Steril. 2006 Dec;86(6):1682-7
17074344
Fertil Steril. 2010 Feb;93(2):374-8
19171336
Fertil Steril. 1996 Jul;66(1):151-3
8752628
Hum Reprod. 2005 May;20(5):1213-20
15760966
Hum Reprod. 1997 Jun;12(6):1129-37
9221989
J Clin Endocrinol Metab. 2002 Feb;87(2):709-15
11836309
J Clin Oncol. 2004 Oct 15;22(20):4174-83
15483028
J Clin Oncol. 2005 Jul 1;23(19):4347-53
15824416
Fertil Steril. 2008 Jan;89(1):84-91
17462639
J Clin Endocrinol Metab. 2006 Oct;91(10):3885-90
16882752
Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):13-20
10428316
J Natl Cancer Inst Monogr. 1994;(16):7-14
7999473
J Clin Oncol. 2006 Jun 20;24(18):2917-31
16651642
J Clin Oncol. 2008 Jun 1;26(16):2630-5
18509175
Hum Reprod. 2005 Oct;20(10):2887-92
15979994